Related Experiment Videos
Drugs targeting the renin-angiotensin-aldosterone system
Mohammad Amin Zaman1, Suzanne Oparil, David A Calhoun
1Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. amin.zaman@ccc.uab.edu
Insights
Antihypertensive therapies reduce cardiovascular disease, but risks remain high. New drugs targeting the renin-angiotensin-aldosterone system offer improved protection by addressing blood pressure and organ damage.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Effective antihypertensive therapy has significantly reduced cardiovascular disease (CVD) morbidity and mortality since the 1960s.
- Conventional blood-pressure-lowering drugs have not fully eliminated CVD risks, leaving residual risk in treated individuals.
- Normotensive individuals exhibit lower cardiovascular disease risks, highlighting the importance of optimal blood pressure control.
Purpose of the Study:
- To evaluate the role of drugs inhibiting or antagonizing the renin-angiotensin-aldosterone system (RAAS).
- To assess the potential of RAAS-targeting drugs in further reducing cardiovascular disease risks.
- To investigate the mechanisms by which these drugs prevent target-organ damage and cardiovascular events.
Main Methods:
- Review of clinical trials and epidemiological studies on antihypertensive therapies.
- Analysis of pharmacological data on drugs affecting the renin-angiotensin-aldosterone system.
- Examination of evidence for the impact of these drugs on cardiac and vascular structure and function.
Main Results:
- RAAS-inhibiting drugs demonstrate efficacy in both lowering blood pressure and mitigating structural/functional abnormalities.
- These agents show promise in preventing target-organ damage, including cardiac hypertrophy and vascular remodeling.
- Evidence suggests a superior cardiovascular risk reduction profile compared to some conventional therapies.
Conclusions:
- Drugs targeting the renin-angiotensin-aldosterone system represent a significant advancement in managing hypertension and its cardiovascular sequelae.
- By addressing both blood pressure and organ-specific damage, these therapies offer enhanced protection against cardiovascular events.
- Further research and clinical application of RAAS-targeting drugs are crucial for optimizing cardiovascular disease prevention.
Abstract:
Effective antihypertensive therapy has made a major contribution to the reductions in the morbidity and mortality of cardiovascular disease that have been achieved since the 1960s. However, blood-pressure control with conventional drugs has not succeeded in reducing cardiovascular disease risks to levels seen in normotensive persons. Drugs that inhibit or antagonize components of the renin-angiotensin-aldosterone system are addressing this deficiency by targeting both blood pressure and related structural and functional abnormalities of the heart and blood vessels, thus preventing target-organ damage and related cardiovascular events.